Alzheimer's disease is a complicated neurological disease characterized by
behavioural defects, memory loss, and progressive cognitive deterioration. Recent
developments in pharmaceutical innovation have demonstrated promise in tackling
fundamental pathogenic pathways, such as neuroinflammation, synaptic dysfunction,
mitochondrial impairments, amyloid-\u03B2 and more. Notable strategies include
synapse-restoring medicines, tau aggregation inhibitors, neuroinflammatory
modulators, and monoclonal antibodies that target amyloid-β2 aggregates. Therapeutic
possibilities are further enhanced by emerging methods such as gene editing and RNAbased therapeutics, as well as biomarkers for personalized medicine. These
developments provide fresh optimism for altering the course of the disease and
enhancing patient outcomes, even though issues like safety profiles and efficient
delivery methods still exist. While tau aggregation inhibitors and anti-tau antibodies are
being studied to reduce the formation of neurofibrillary tangles, monoclonal antibodies
such as aducanumab and lecanemab have shown potential in reducing the amyloid
plaque burden. Neuroinflammation is a key player in the widespread pathology of
Alzheimer’s disease, and drugs that alter microglial activity or stop pro-inflammatory
cytokines such as TNF-α and IL-1β are used to combat it. Due to growing
understanding of the meaning of mitochondrial dysfunction, mitophagy activators and
mitochondrial protectants have been developed to preserve the energy balance of
neurons. Gene and RNA-based therapies may hold promise for precision medicine,
including CRISPR/Cas9 editing and antisense oligonucleotide platforms that allow us
to correct protein expression and genetic factors to more precisely address genetic and
phenotypic variables. Moreover, advances in imaging and fluid biomarkers are
enabling more personalized treatment plans and improved early detection. Though
challenges still remain, including in managing side effects and delivering medications
across the blood-brain barrier, these developments represent a significant breakthrough in the fight against Alzheimer’s. Future efforts must prioritize cross-disciplinary
approaches integrating lifestyle shifts with pharmaceutical advancements to enable
complete illness remediation.
Keywords: Alzheimer’s disease, Diagnosis, Emerging innovation, Gene therapy, Tau aggregation inhibitors, Treatment.
